BFM
NAMS icon

Boothbay Fund Management’s NewAmsterdam Pharma NAMS Stock Holding History

Boothbay Fund Management’s Portfolio NAMS Stock Details NAMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-57,600
Closed -$1.48M – 1651
2024
Q4 		$1.48M Buy
+57,600
New +$1.22M 0.04% 526

Other funds holding NAMS

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
DFO
Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return

Boothbay Fund Management's NAMS Position: Q1 2026 in Review

Boothbay Fund Management reduced its NewAmsterdam Pharma (NAMS) stake by 19% in Q1 2026, selling an estimated $214K and leaving 27,336 shares worth $875K. The position accounts for 0.01% of the portfolio, ranked #1015.

Boothbay Fund Management first reported a position in NAMS in Q4 2024 and has held it in 6 quarters since. The position peaked at $2.64M in Q1 2025. 170 funds tracked by Wall St. Rank hold NAMS as of Q1 2026.

  • Boothbay Fund Management held 27,336 shares of NewAmsterdam Pharma worth $875K as of Q1 2026.
  • Boothbay Fund Management sold 6,583 NewAmsterdam Pharma shares in Q1 2026, an estimated $214K.
  • NewAmsterdam Pharma made up 0.01% of Boothbay Fund Management's portfolio in Q1 2026, its #1015 holding.
  • Boothbay Fund Management first reported a position in NewAmsterdam Pharma in Q4 2024 and has held it in 6 quarters since.
  • Boothbay Fund Management's NewAmsterdam Pharma position peaked at $2.64M in Q1 2025.
  • 170 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q1 2026.

Based on Boothbay Fund Management's 13F filing for Q1 2026, filed 15 May 2026.